BidaskClub upgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a hold rating to a buy rating in a research report sent to investors on Saturday morning.

A number of other equities analysts have also commented on ESPR. Jefferies Group reaffirmed a buy rating and set a $85.00 target price on shares of Esperion Therapeutics in a research report on Monday, August 21st. Zacks Investment Research raised shares of Esperion Therapeutics from a sell rating to a hold rating in a research report on Wednesday, August 23rd. Northland Securities started coverage on shares of Esperion Therapeutics in a research report on Tuesday, August 29th. They set an outperform rating and a $72.00 target price on the stock. Cowen started coverage on shares of Esperion Therapeutics in a research note on Thursday, September 7th. They set an outperform rating and a $64.00 price objective on the stock. Finally, Stifel Nicolaus reiterated a buy rating and set a $70.00 price objective on shares of Esperion Therapeutics in a research note on Wednesday, October 4th. Seven analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of Buy and an average price target of $60.85.

Esperion Therapeutics (ESPR) opened at $61.55 on Friday. Esperion Therapeutics has a 1 year low of $10.71 and a 1 year high of $65.20.

Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.07). During the same period last year, the firm earned ($0.77) EPS. research analysts predict that Esperion Therapeutics will post -7.3 earnings per share for the current year.

In other news, Director Nicole Vitullo sold 9,326 shares of the stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $53.85, for a total transaction of $502,205.10. Following the transaction, the director now directly owns 2,472 shares in the company, valued at $133,117.20. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 32.50% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Tower Research Capital LLC TRC boosted its stake in Esperion Therapeutics by 69,371.4% in the second quarter. Tower Research Capital LLC TRC now owns 4,863 shares of the biopharmaceutical company’s stock valued at $225,000 after acquiring an additional 4,856 shares in the last quarter. Aperio Group LLC acquired a new stake in Esperion Therapeutics in the second quarter valued at approximately $249,000. SG Americas Securities LLC boosted its stake in Esperion Therapeutics by 74.5% in the second quarter. SG Americas Securities LLC now owns 7,008 shares of the biopharmaceutical company’s stock valued at $324,000 after acquiring an additional 2,991 shares in the last quarter. Voya Investment Management LLC boosted its stake in Esperion Therapeutics by 12.7% in the second quarter. Voya Investment Management LLC now owns 7,148 shares of the biopharmaceutical company’s stock valued at $331,000 after acquiring an additional 806 shares in the last quarter. Finally, State of Wisconsin Investment Board acquired a new stake in Esperion Therapeutics in the second quarter valued at approximately $509,000. Institutional investors own 92.28% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/esperion-therapeutics-espr-upgraded-at-bidaskclub/1772087.html.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.